OncoMatch/Clinical Trials/NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Is NCT07028853 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Mevrometostat and Enzalutamide for metastatic castration sensitive prostate cancer (mcspc).
Treatment: Mevrometostat · Enzalutamide — This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: cytotoxic chemotherapy
Exception: first-generation antiandrogen (ADT) agents allowed for mCSPC
Participants must be treatment naïve at the mCSPC stage, eg, participants cannot have received any cytotoxic chemotherapy with the following exceptions: Treatment with first-generation antiandrogen (ADT) agents is allowed for mCSPC.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clearview Cancer Institute (Crestwood) · Huntsville, Alabama
- Clearview Cancer Institute · Huntsville, Alabama
- Ironwood Cancer & Research Centers · Chandler, Arizona
- Ironwood Cancer & Research Centers · Gilbert, Arizona
- Ironwood Cancer & Research Centers · Glendale, Arizona
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07028853 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages